Trial Profile
Efficacy and Safety of Albuvirtide for Injection Combined With LPV/r for Treatment of HIV-1-Infected Patients Failed First-line Antiretroviral Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Labuvirtide (Primary) ; Lamivudine; Lopinavir/ritonavir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms TALENT
- Sponsors Frontier Biotechnologies
- 21 Jul 2021 Results presented at the 11th International AIDS Society Conference on HIV Science
- 19 Jul 2021 Results from this trial were presented at the 11th International AIDS Society (IAS) Conference on HIV Science.
- 19 Jul 2021 Top-line Results published in Frontier Biotechnologies Media Release.